metildigoxin 🐶 Veterinary Use | Indications/Contra | FAERs-F | FAERs-M | Orange Bk | BioActivity |

Stem definition	Drug id	CAS RN
	1761	30685-43-9

Description:

Molecule	Description
Molfile Inchi Smiles Synonyms: methyldigoxin metildigoxin 4'-Methyldigoxin lanirapid lanitop medigoxin beta-Methyldigoxin	A semisynthetic digitalis glycoside with the general properties of DIGOXIN but more rapid onset of action. Its cardiotonic action is prolonged by its demethylation to DIGOXIN in the liver. It has been used in the treatment of congestive heart failure (HEART FAILURE). Molecular weight: 794.98 Formula: C42H66O14 CLOGP: 1.73 LIPINSKI: 2 HAC: 14 HDO: 5 TPSA: 192.06 ALOGS: -4.12 ROTB: 8

Molecule

Description

Molfile Inchi Smiles

Synonyms:

methyldigoxin
metildigoxin
4'-Methyldigoxin
lanirapid
lanitop
medigoxin
beta-Methyldigoxin

A semisynthetic digitalis glycoside with the general properties of DIGOXIN but more rapid onset of action. Its cardiotonic action is prolonged by its demethylation to DIGOXIN in the liver. It has been used in the treatment of congestive heart failure (HEART FAILURE).

Molecular weight: 794.98
Formula: C42H66O14
CLOGP: 1.73
LIPINSKI: 2
HAC: 14
HDO: 5
TPSA: 192.06
ALOGS: -4.12
ROTB: 8

Drug dosage:

Dose	Unit	Route
0.20	mg	O
0.20	mg	P

ADMET properties:

Property	Value	Reference
MRTD (Maximum Recommended Therapeutic Daily Dose)	0.01 µM/kg/day	Contrera JF, Matthews EJ, Kruhlak NL, Benz RD
BDDCS (Biopharmaceutical Drug Disposition Classification System)	3	Bocci G, Oprea TI, Benet LZ

Approvals:

None

FDA Adverse Event Reporting System (Female)

MedDRA adverse event term	Likelihood ratio	Likelihood ratio threshold	Patients taking drug having adverse event	Patients taking drug not having adverse event	Patients not taking drug having adverse event	Patients not taking drug not having adverse event
Cardiac failure	60.19	33.17	30	1098	89112	63398782
Wound haemorrhage	55.22	33.17	12	1116	2504	63485390
Toxic neuropathy	54.73	33.17	9	1119	419	63487475
Bradycardia	53.44	33.17	26	1102	73201	63414693
Refractory anaemia with an excess of blasts	47.36	33.17	8	1120	439	63487455
Haematoma	33.54	33.17	15	1113	34805	63453089
Troponin T increased	33.29	33.17	7	1121	1247	63486647

FDA Adverse Event Reporting System (Male)

MedDRA adverse event term	Likelihood ratio	Likelihood ratio threshold	Patients taking drug having adverse event	Patients taking drug not having adverse event	Patients not taking drug having adverse event	Patients not taking drug not having adverse event
Cardiac failure chronic	52.42	36.94	16	992	7863	34948060
Cardiac failure	46.02	36.94	30	978	91218	34864705
N-terminal prohormone brain natriuretic peptide increased	38.63	36.94	10	998	2705	34953218
Aortic stenosis	38.38	36.94	11	997	4347	34951576

FDA Adverse Event Reporting System (Geriatric)

MedDRA adverse event term	Likelihood ratio	Likelihood ratio threshold	Patients taking drug having adverse event	Patients taking drug not having adverse event	Patients not taking drug having adverse event	Patients not taking drug not having adverse event
Cardiac failure	99.55	31.31	58	2089	154784	79587457
Cardiac failure chronic	64.40	31.31	20	2127	11115	79731126
Wound haemorrhage	44.23	31.31	12	2135	4149	79738092
Toxic neuropathy	43.54	31.31	9	2138	971	79741270
N-terminal prohormone brain natriuretic peptide increased	42.65	31.31	12	2135	4743	79737498
Cerebral infarction	39.91	31.31	21	2126	45655	79696586
Refractory anaemia with an excess of blasts	38.38	31.31	8	2139	898	79741343
Aortic stenosis	37.26	31.31	12	2135	7483	79734758
Congestive cardiomyopathy	35.63	31.31	13	2134	11767	79730474
Bradycardia	34.91	31.31	29	2118	135528	79606713
Dyspnoea	33.58	31.31	72	2075	856953	78885288

FDA Adverse Event Reporting System (Pediatric)

None

Pharmacologic Action:

Source	Code	Description
ATC	C01AA08	CARDIOVASCULAR SYSTEM CARDIAC THERAPY CARDIAC GLYCOSIDES Digitalis glycosides
MeSH PA	D000889	Anti-Arrhythmia Agents
MeSH PA	D002316	Cardiotonic Agents
MeSH PA	D002317	Cardiovascular Agents
MeSH PA	D004791	Enzyme Inhibitors
MeSH PA	D020011	Protective Agents

Drug Use | Suggest Off label Use Form| |View source of the data|

None

🐶 Veterinary Drug Use

None

🐶 Veterinary products

None

Acid dissociation constants calculated using MoKa v3.0.0

None

Orange Book patent data (new drug applications)

None

Orange Book exclusivity data (new drug applications)

None

Bioactivity Summary:

Target	Class	Pharos	UniProt	Action	Type	Activity value (-log[M])	Mechanism action	Bioact source	MoA source
Sodium/potassium-transporting ATPase subunit alpha-1	Transporter	P05023	AT1A1_HUMAN					WOMBAT-PK

External reference:

ID	Source
N0000168450	NUI
D02587	KEGG_DRUG
C0025132	UMLSCUI
CHEBI:135885	CHEBI
CHEMBL1697843	ChEMBL_ID
DB13401	DRUGBANK_ID
2876	INN_ID
I7GG1YUC5V	UNII
443946	PUBCHEM_CID
6686	RXNORM
006744	NDDF
317911001	SNOMEDCT_US
418574005	SNOMEDCT_US
D008520	MESH_DESCRIPTOR_UI

Pharmaceutical products:

None